Australia markets closed

AcelRx Pharmaceuticals Inc (R5XA.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
0.91800.0000 (0.00%)
At close: 08:04AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
651
651
0
2,818
5,416
-
Cost of revenue
-
-
2,591
3,753
6,032
6,806
Gross profit
-
-
-820
-935
-616
-4,517
Operating expenses
Research development
5,932
5,546
3,341
4,095
4,017
-
Selling general and administrative
10,517
11,994
17,011
30,935
36,330
-
Total operating expenses
16,449
17,540
20,352
35,030
40,347
-
Operating income or loss
-15,798
-16,889
-20,352
-35,965
-40,963
-
Interest expense
196
134
1,116
2,291
3,305
-
Total other income/expenses net
-
-
79,104
-
-
-
Income before tax
-14,305
-10,287
59,138
-35,094
-40,375
-
Income tax expense
-
0
13
5
4
-
Income from continuing operations
-14,305
-10,287
59,125
-35,099
-40,379
-
Net income
-14,199
-18,397
47,755
-35,099
-40,379
-
Net income available to common shareholders
-14,199
-18,397
42,329
-35,099
-40,379
-
Basic EPS
-2.04
-1.29
5.73
-5.86
-9.40
-
Diluted EPS
-2.04
-1.29
5.72
-5.86
-9.40
-
Basic average shares
11,541
14,264
7,385
5,993
4,263
-
Diluted average shares
11,558
14,264
7,407
5,993
4,263
-